David and Goliath stories are common place throughout history, with some of the more notable instances occurring in the business world. They often involve a smaller, nimble upstart disrupting a large, entrenched player through a combination of grit and ingenuity, particularly in fast-paced industries shaped by technological innovation. More often, however, the little guys simply coexist with the giants by forming a profitable niche that's underserved and underappreciated, a market where they can gain a foothold and grow.
That's the case with one of the best-performing stocks in the biopharma industry today: Santarus . Up around 10% on a recent FDA approval, follow along in the video below as Brenton discusses one of the health care growth stories you've never heard of.
What's inside Supernova?
If you're an investor looking for big long-term winners, Motley Fool co-founder David Gardner's picks have frequently trounced the market. How? Because he's always on the lookout for revolutionary stocks and recommends them before Wall Street catches on to their disruptive potential. If you're interested in how David discovers his winners, click here to get instant access to a personal tour behind David's Supernova service.
The article Santarus Soars on FDA Approval originally appeared on Fool.com.
Brenton Flynn has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.